N/A N=36 Mercury Metabolism by Bacteria in Humans
Mercury--Toxicology
Primary: Mercury Elimination Rate Before Pre-biotic — 48.5 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=56 Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study
Contact Dermatitis
Primary: Number of Participants Who Exhibit Positive Responses to Each Allergen Concentration — 4; 0; 0; 2 Participants
N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
Phase 2 N=36 In Vivo Assessment of Silver Biomaterial Nano-Toxicity
Healthy
Primary: Change in Sodium Blood Levels — -0.1; 0.2 mmol/L
Phase 2 N=12 In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
Healthy
Primary: Change Sodium Blood Levels — 141.8; 141.2 mmol/L
Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
Phase 4 N=60 A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh
Arsenic Metabolites Measured in Urine
Primary: Change in Urinary % Monomethyl Arsenic — 2.4; 0.24; -0.06; -3.2 percentage of total urinary arsenic
Early Phase 1 N=8 Benzo[a]Pyrene Ultralow Dose-Response Study
Environmental Exposure
Primary: Peak Plasma Concentration Cmax — 2.51; 5.68; 13.8; 8.99 fg [14C]-BaP/mL plasma
N/A N=85 Assessing Toxicity of Waterpipe Tobacco Smoking
Waterpipe Smoking
Primary: Comparing Cotinine Pre-to-post Change Between 2 Waterpipe Smoking Sessions: Heating Waterpipe Tobacco by (a) Charcoal vs (b) an Electric Head — 34.9; 26.4 ng/mL — p=0.115
N/A N=102 European Survey: Risk of Cyanide Poisoning in Smoke Inhalation
Smoke Inhalation Patients
Primary: Overall Survival After 24 Hours — 96 participants
Phase 2 N=48 Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
Multiple Myeloma · Stem Cell Transplantation
Primary: Response Rate — 11; 36 Participants
N/A N=434 Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age
Endocrine Disrupting Chemicals · Environmental Exposure · Health Literacy
Primary: Changes in Endocrine Disrupting Chemical (EDC) Levels as Measured by the Post-intervention Value Minus the Baseline Value. — 5.83; 18.43; 56.94; 75.30 ng/ml — p=<0.05
Phase 2 N=300 Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens
Healthy
Primary: Carcinogen Detoxification of Metabolites in Urine. — 7.26; 6.11; 3052.39; 1843.29 ng/mL
N/A N=15 Effect on Acetaminophen Metabolism by Liquid Formulations
Acetaminophen Metabolism · Acetaminophen Poisoning · Drug Metabolism by Excipients
Primary: Acetaminophen Metabolites — 2.411; 2.009 mcg.hr/ml
Phase 4 N=21 Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing
Acetaminophen Toxicity
Primary: Rise in Plasma Transaminases: Proportion of Responders. — 6; 8 Participants — p=0.59
Phase 1 N=26 Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation
Cannabis Toxicology
Primary: Delta-9-tetrahydrocannabinol (THC) Cmax in Blood — 1.4; 3.07; 0.5 ng/mL
Early Phase 1 N=8 Ultralow Dose PAH Binary Mixture Study
Environmental Exposure
Primary: Peak Plasma Concentration of 14C-BaP Cmax — 7.07; 1.60 fg [14C]-BaP/mL plasma
Phase 2 N=234 Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"
Dietary Carcinogenesis
Primary: AFB1-lysine Adduct (pg/mg) Overtime — 3.77; 4.09; 4.26; 3.00 pg/mg albumin
Phase 1 N=38 Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment
Healthy
Primary: Skin Reaction Score — 0.4; 0.5; 0.1; 0.4 units on a scale
Phase 2 N=50 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Cancer Other Than Leukemia
Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg
Phase 2 N=50 Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Dermatitis, Contact
Primary: Analysis of Bioequivalence: Concordance — 76; 98.0 percentage of agreement
Early Phase 1 N=28 Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama
Toxic Effect of Other Corrosive Organic Compounds
Primary: Percent Change From Baseline for Total PCB Levels — 92; 96 % of baseline total PCBs
Phase 2 N=170 Broccoli Sprout Dose Response: Bioavailability and Effects of Air Pollutants
Environmental Carcinogenesis
Primary: Sulforaphane Bioavailability Measured in Sequential 12-Hour Urine Samples — 24.8; 11.0; 4.3 micromoles/24 hours — p=<0.001
N/A N=300 Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta
Liver Cancer
Primary: Serum Aflatoxin Level in Liver Cancer Patients — 7.96; 6.10; 4.13 ng\ml
N/A N=70 Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
Oxidative Stress · Inflammation · Blood Pressure
Primary: Biomarkers of Antioxidant Activity-Total Antioxidant Capacity (TAC) and Superoxide Dismutase (SOD) — 6.09; 5.80; 364.34; 356.59 U/ml
N/A N=20 Bisphenol A in Saliva and Urine Related to Placement of Dental Composites
Dental Polymer Based Filling Material
Primary: Concentration of Bisphenol A in Saliva — 0.25 ng/ml — p=<0.05